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Performance in the Management of
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Purpose: The aim of this study was to evaluate the results of the surgical treatment of bisphosphonate-
related osteonecrosis of the jaw (BRONJ) in a large cohort.
Materials and Methods: A retrospective cohort multicenter study was designed. Patients were
enrolled if they were diagnosed with BRONJ and received operative treatment. Data on demographic,
health status, perioperative, and surgical factors were collected retrospectively. The primary outcome
variable was a change in BRONJ staging (improvement, worsening, or no change). Interventions were
grouped by local debridement and resective surgery. Data were collected for other variables as cofactors.
Univariate analysis and logistic regressions were then performed.
Results: Of the 347 BRONJ-affected subjects, 59% showed improvement, 30% showed no change, and
11% showed worsening. Improvement was observed in 49% of cases treated with local debridement and
68% of cases treated with resective surgery. Multivariate analysis indicated that maxillary location,
resective surgery, and no additional corticosteroid treatment were associated with a positive outcome.
Conclusions: Surgical treatment of BRONJ appeared to be more effective when resective procedures
were performed. Nonetheless, other factors, such as the absence of symptoms and the types of drug
administration, should be taken into account before clinical decisions are made.
© 2012 American Association of Oral and Maxillofacial Surgeons
J Oral Maxillofac Surg 70:2501-2507, 2012
Received from the Department of Surgery, University of Pisa, Pisa,
Italy.
*Assistant Clinical Professor, Section of Oral Surgery.
†Associate Professor, Department of Otolaryngologic/Dental/
Ophthalmological and Cervicofacial Sciences, University of Parma,
Parma, Italy.
‡Associate Professor, Sector of Oral Medicine “‘V. Margiotta’”,
Department of Oral Sciences, University of Palermo, Palermo, Italy.
§Full Professor, Department of Odontostomatology and Surgery,
University of Bari, Bari, Italy.
Full Professor, Section of Oral Surgery.
¶Contract Professor, Department of Odontostomatologic, Orthodontic
and Surgical Disciplines, Second University of Naples, Naples, Italy.
#Research Fellow, Section of Oral Surgery; PhD student, Depart-
ment of Periodontology, University of Milano-Bicocca, Milan, Italy.
**Head Physician, Unit of Odontostomatology, Ospedale Mauri-
††Research Fellow, Biostatistics Unit.
‡‡Head Physician, Unit of Maxillofacial Surgery and Odontos-
tomatology, San Sebastiano Hospital, Caserta, Italy.
§§Consultant, Oral Surgery Unit, Dentistry Section, Department
of Clinical Physiopathology, University of Turin, Turin, Italy.
 Head Physician, Maxillofacial Surgery, ARNAS Ospedale Civico,
Palermo, Italy.
¶¶Associate Professor, Department of Head and Neck Surgery,
Second University of Naples, Naples, Italy.
Address correspondence and reprint requests to Dr Graziani:
Department of Surgery, Section of Oral Surgery, University of Pisa,
Via Roma, 67, 56126 Pisa, Italy; e-mail: filippo.graziani@med
.unipi.it
© 2012 American Association of Oral and Maxillofacial Surgeons
0278-2391/12/7011-0$36.00/0ziano Umberto I, Turin, Italy.
http://dx.doi.org/10.1016/j.joms.2012.05.019
2501
s
a
s
l
s
a
t
m
w
a
c
t
s
t
c
n
i
f
r
t
a
a
I
m
t
m
A
t
t
p
i
r
t
a
c
2502 SURGICAL TREATMENT OF BRONJBisphosphonates (BPs) are unstable equivalents of
pyrophosphate that bind selectively to the bone and
are supposed to act selectively on osteoclasts during
high bone turnover, resulting in an antiresorptive
effect.1,2 BPs are used widely in the management of
ystemic metabolic disorders, such as osteoporosis
nd Paget disease.3 Long-term BP endovenous infu-
ion is administered to control hypercalcemia in ma-
ignant cases and to prevent skeletal complications,
uch as pathologic fractures or nerve compressions
ssociated with bone metastasis, in different solid
umors, including breast, prostate, and lung cancers.4
However, BPs are strongly related to the develop-
ment of a form of osteonecrosis of the jaws.5,6 BP-
related osteonecrosis of the jaws (BRONJ) has been
clearly defined as a clinical scenario characterized by
3 diagnostic features: 1) current or previous treat-
ent with a BP; 2) the presence, for longer than 8
eeks, of exposed bone in the maxillofacial region;
nd 3) no history of radiation therapy to the jaws.7
Moreover, recent evidence has suggested that a non-
exposed form of BRONJ may represent an insidious
clinical variant that clinicians should always consider
in their diagnostic process.8,9 The dental and medical
ommunities are currently aware of this clinical en-
ity. Clinical and research evidence is increasing, and
everal cases have been identified.6
BRONJ management is under debate within the
medical and dental communities. Conservative ap-
proaches such as drug interventions,10 hyperbaric
reatment,11 and laser applications12 have been advo-
cated to decrease the symptoms and frequency of
disease recurrence. In contrast, surgical management
has been suggested to address necrotic bone expo-
sures13,14 but appears to produce controversial clini-
al outcomes. Indeed, the results may be affected by
umerous variables, such as current staging, the tim-
ng of the intervention, the technique used, the need
or reconstruction, and the extent of the resection (ie,
esective or local debridement). However, the data on
he surgical management of BRONJ are very limited
nd usually associated with a single center.
Therefore, the purpose of this study was to collect
nd analyze the data from 9 clinical centers throughout
taly to describe and assess the outcomes of the surgical
anagement of BRONJ. The investigators hypothesized
hat some factors, such as changes in clinical staging,
ay be associated with positive clinical outcomes.
mong these, some characteristics of surgical interven-
ion, such as bone removal, were observed. Therefore,
he specific aims of the study were to describe the
ercentages of improvement in clinical staging accord-
ng to the type of intervention (with or without bone
emoval) and the characteristics of the population.Materials and Methods
STUDY DESIGN AND SAMPLE
To address the research hypothesis, the investiga-
tors designed a retrospective study involving 9 clini-
cal centers throughout Italy: 6 in southern Italy; 1 in
central Italy; and 2 in northern Italy. The centers in
northern Italy included a broader network of 20 clin-
ical departments, such as oral medicine; oral surgery;
maxillofacial surgery; ear, nose, and throat; and he-
matology, and medical oncological units across the
entire Piedmont region (Table 1). Because of the
retrospective nature of this study, involving only rou-
tine procedures, IRB approval was not necessary.
Eligible subjects were identified from the patients
of the respective clinical centers. The trial included
only those 1) diagnosed with BRONJ, 2) surgically
reated for BRONJ, 3) whose clinical files were avail-
ble, and 4) treated from January 2004 through De-
ember 2008 with at least a 12-month follow-up.
STUDY VARIABLES AND DATA COLLECTION
Surgical outcome, the primary outcome, was as-
sessed based on a 3-degree scale: improvement, no
modification, or worsening.15 Improvement was de-
fined as transition to a less severe stage, according to
the classification of Ruggiero et al,16 6 months after
the surgical intervention. The calibration of BRONJ
was carried out by the researchers in 3 national
BRONJ meetings. During data collection, disagree-
ments were resolved after a discussion with the study
coordinator (G.C.).
The descriptive analysis was performed based on
the 3-degree scale. Inferential statistical analysis also
was performed, with negative outcomes (no modifi-
cation and worsening) grouped to increase the clini-
cal relevance of the data.
Each outcome was then analyzed according to a set
of predictor variables: demographic; health; perioper-
ative; and operative.
Operative variables were grouped according to the
types of surgical interventions and were divided into 2
procedural categories: local debridement and resection.
Local debridement was comprised of all surgical inter-
ventions, such as sequestrectomy, soft tissue debride-
ment, and curettage, that did not require bone surgery
beyond the regular margins. Resective procedures were
defined as corticotomy, surgical removal of the lesion,
and extended bone removal without prejudice for the
continuity of the mandible/maxilla. The choice of the
type of intervention was based on the personal experi-
ence of the surgeon.
DATA ANALYSES
Data were entered into an Excel 2003 (Microsoft,
Redmond, WA) database and proofread for entry er-
urg 20
GRAZIANI ET AL 2503rors. The database was subsequently locked, im-
ported into SPSS 17.0 for Windows (SPSS, Inc, Chi-
cago, IL) and R 2.10 (Statistics Department of the
University of Auckland, Auckland, New Zealand), for-
matted, and analyzed. The statistician was masked by
the assignment of Greek letters to the variables. The
Cramér-von-Mises and Shapiro-Wilk tests were used to
check the normality of data distribution and assess
whether parametric tests should be performed. The
introductory phase was concluded with a statistical
power analysis (retrospective) to estimate the sample
size required for the specific tests. For significant
variables, the 1   value was mostly higher than 0.8,
ensuring a low risk of type II error in univariate
analysis. Univariate analysis was performed by the t
test or the Mann-Whitney test, according to the nor-
mality of continuous data distribution, whereas the 2
test with the Yates correction for continuity was used
for the percentage data. Probabilities were deter-
mined with 95% confidence intervals. Logistic regres-
sions were then applied in a generalized linear model
Table 1. PREOPERATIVE CLINICAL VARIABLES VERSUS
Preoperative Clinical Variables Local D
Demographic variables
Men (%) 73
Age (yr) 67.2
Clinical variables
Anatomic location
Mandible 154
Maxilla 59
Mandible/maxilla 14
Dehiscence 170
Bone exposure 163
Pus 118
Fistula 41
Radiologic signs of necrosis 102
Pain 157
Absence of symptoms 11
Stage
I 91
II 109
III 27
Operator
Maxillofacial surgeon 107
Oral-maxillofacial pathologist 32
DDS/DMD 27
Oral surgeon 61
Previous extraction 148
Pharmacologic and medical variables
Bisphosphonate endovenous infusion 213
Length of therapy (mo) 24
Cortisone 89
Chemotherapy 173
Diabetes 27
Other pathologies 70
Graziani et al. Surgical treatment of BRONJ. J Oral Maxillofac Sused for binomial regression, with the outcome of sur-gical intervention as a dependent dichotomy variable
(improved/not worse). The regression was performed
according to the initial stage.
Results
SAMPLE CHARACTERISTICS
For the survey, 347 subjects (230 women, 66%;
average age, 67 yr; standard deviation, 11 yr; age
range, 34 to 92 yr) were selected. An oncologic diag-
nosis had been made in most cases (90%). Multiple
myeloma was the primary pathology in 36% of cases
(126 subjects), followed by breast cancer in 29% (99
subjects), and prostate cancer in 10% (34 subjects).
Forty-three subjects received BPs for osteoporosis
treatment (12%). Other indications were chest, colon,
and thyroid tumors. Thirty percent of the subjects
also had concomitant pathologies. Nine percent of
the subjects had diabetes, 20% had hypertension, and
7% had heart disease. BP administration was mainly
RY PREDICTOR VARIABLE
ment Resective Intervention P Value
) 36 (30%) .8
.5 65.6  11.7 .3
.006
) 74 (62%)
) 46 (38%)
0 (0%)
) 116 (97%) .0001
) 98 (82%) .1
) 89 (74%) .0006
) 16 (13%) .4
) 125 (5%) .0001
) 92 (77%) .2
18 (15%) .002
.0001
) 17 (14%)
) 94 (78%)
) 10 (8%)
.0001
) 11 (9%)
) 2 (2%)
) 1 (1%)
) 106 (88%)
) 86 (72%) .2
) 96 (80%) .002
22  10 .0001
) 28 (23%) .007
) 82 (68%) .2
) 6 (5%) .7
) 29 (24%) .2
12.PRIMA
ebride
(32%
 10
(68%
(26%
(6%)
(75%
(72%
(52%
(18%
(45%
(69%
(5%)
(40%
(48%
(12%
(47%
(14%
(12%
(27%
(65%
(94%
 20
(39%
(76%
(12%
(31%endovenous (88%). The BPs used were zoledronate
DC
2504 SURGICAL TREATMENT OF BRONJ(241 subjects, 60%), followed by pamidronate (42
subjects, 10%), alendronate (31 subjects, 8%), clodro-
nate (13 subjects, 3%), and risedronate (3 subjects,
1%). Ibandronate and neridronate were taken by 2
separate subjects. The identification of BPs used
was not possible in the remaining 15 subjects. The
BP treatment was administered for an average of 23
months (range, 1 to 71 mo; 95% confidence inter-
val, 20 to 24 mo) before the BRONJ diagnosis. One
hundred fourteen subjects (33%) also received cor-
ticosteroids.
The BRONJ lesions were mainly symptomatic (319
subjects, 92%), and bone exposure was detectable in
the vast majority of cases (305 subjects, 88%). Pus was
detected in 56% of cases (181 subjects) and fistulas in
17% (57 subjects). Sixty-five percent of the lesions
were located in the mandible (226 subjects), 29%
(100 subjects) in the maxilla, and 6% in the maxilla
and mandible. The main event leading to BRONJ was
extraction (212 subjects, 63%). A reasonable explana-
tion for BRONJ was detected in 68% of cases (226
subjects). Prosthetic trauma was detected in 9 cases
(3%), and periodontal disease, osteitis, and other
causes accounted for 1% (5 subjects) of the total. The
most frequent stage of BRONJ was stage II (208 sub-
jects, 60%), whereas stage I (96 subjects, 28%) and
stage III (34 subjects, 10%) were less common. The
stages in the remaining 2% of the sample were not
classified.
CLINICAL DATA
During follow-up, after the first 6 months, 51 sub-
jects (15%) died. Most treatments were performed by
a dental graduate (242 cases, 70%), whereas the re-
maining subjects were treated by a maxillofacial sur-
geon. The surgical interventions consisted mainly of
local debridement (66%).
For the surgical outcome, 59% of subjects showed
improvement after surgery, 30% showed no change,
and 11% exhibited a worsening of their clinical con-
dition. Univariate analysis of the factors affecting the
outcome indicated that several preoperative clinical
variables were associated with the clinical outcome
(Table 1). The presence of preoperative clinical symp-
toms, such as pain, pus discharge, and fistulas, was
associated with a negative prognosis. In particular,
the location of the lesion (mandible), the administra-
tion of cortisone/endovenous BPs, and radiologic
signs of necrosis were strongly associated with nega-
tive outcomes.
The characteristics of the 2 study populations (sur-
gical debridement vs resective surgery) are presented
in Table 2.
After surgical debridement, 49% of cases showed
improvement, with no improvement in 35% andworsening in the remaining 16%. Resective surgery
resulted in a statistically significant difference (P 
.002) because improvement was seen in 68%, with
no improvement in 27% and a worse clinical con-
dition in 5%.
Analysis showed positive outcomes (Table 3) in
patients with stage II lesions treated with resective
surgery. Conversely, patients with stage I lesions
treated with local debridement showed greater, albeit
modest, improvement. Those with stage III lesions
showed no significant clinical improvement.
Logistic regression indicated that treatment, drug
administration, and the location of the lesion could
Table 2. PROGNOSTIC VALUES OF PREOPERATIVE
CLINICAL VARIABLES VERSUS PRIMARY OUTCOME
Preoperative Clinical
Variables
Positive
Outcome
Negative
Outcome
P
Value
emographic variables
Age (yr) 66.9  10.6 67.5  11.2 .6
Men (%) 65 (31%) 46 (33%) .8
linical variables
Anatomic location .0003
Mandible 119 (57%) 109 (79%)
Maxilla 79 (38%) 23 (17%)
Mandible/maxilla 10 (5%) 6 (4%)
Dehiscence 194 (93%) 113 (82%) .04
Exposure 153 (73%) 121 (88%) .004
Pus 113 (54%) 90 (65%) .05
Fistula 25 (12%) 29 (21%) .05
Radiologic signs of
necrosis
50 (24%) 73 (53%) .0001
Pain 146 (70%) 112 (81%) .04
Absence of symptoms 17 (8%) 12 (9%) .9
Stage .1
I 65 (31%) 35 (25%)
II 127 (61%) 88 (64%)
III 17 (8%) 15 (11%)
Operator .07
Maxillofacial
surgeon
72 (34%) 65 (47%)
Oral-maxillofacial
pathologist
15 (7%) 11 (8%)
DDS/DMD 15 (7%) 10 (7%)
Oral surgeon 108 (52%) 52 (38%)
Previous extraction 140 (67%) 97 (70%) .6
Pharmacologic and
medical variables
Bisphosphonate
endovenous
infusion
178 (85%) 130 (94%) .003
Length of therapy
(mo)
25  19 21  17 .07
Cortisone 54 (74%) 61 (56%) .0006
Chemotherapy 140 (67%) 108 (78%) .06
Diabetes 15 (7%) 15 (11%) .4
Other pathologies 61 (29%) 44 (32%) .6
Graziani et al. Surgical treatment of BRONJ. J Oral Maxillofac
Surg 2012.affect the outcome (Table 4).
a
o
d
s
e
e
A
s
a
T
s
I
f
p
a
n
9
i
w
b
f
p
A
G
L
P
P
C
O
S
O
S
N
1
t
t
n
GRAZIANI ET AL 2505Discussion
This study retrospectively assessed, in a large co-
hort, the clinical results of different surgical interven-
tions performed as part of the management of sub-
jects affected by BRONJ. The rationale for the study
was based on the hypothesis that some clinical factors
may be prognostically associated with positive clini-
cal outcomes. The primary focus was on the type of
surgical intervention. Therefore, the specific aims of
the study were to describe the percentage of improve-
ment of clinical staging according to the type of in-
tervention (with or without bone removal) and ac-
cording to some characteristics of the population.
Table 3. PRIMARY PREDICTOR VARIABLE VERSUS
PRIMARY OUTCOME
Predictor Variable
Outcome Variable
Total
Positive
Outcome
Negative
Outcome
Local debridement 122 105 227
Resective surgery 87 33 120
Total 209 138 347
Note: A relative risk lower than 1 indicates a protective
effect against a negative outcome, whereas a relative risk
higher than 1 indicates a tendency toward a negative out-
come. The relative risk for subjects who underwent resec-
tive surgery (reference group) is 0.7 (confidence interval,
0.4 to 0.8; P  .002). Therefore, a resective intervention
seems to have a significant protective effect against a neg-
ative outcome. The risk of subjects after a resective inter-
vention to have a negative outcome is 30% lower than in
subjects after local debridement.
Graziani et al. Surgical treatment of BRONJ. J Oral Maxillofac
Surg 2012.
Table 4. MULTIVARIATE LOGISTIC REGRESSION OF FAC
Factors Influencing Outcome Reference
ge 10 yr older
ender Male
ocation Maxilla
us Absence
ain No pain
orticosteroid No corticostero
ral administration of BPs BPs
tage 1 stage higher
perator DDS/DMD
urgical intervention Resective inter
ote: An odds ratio lower than 1 indicates a protective effe
indicates a tendency to a negative outcome. Significant
reatment, and location. The probability of subjects not trea
han in the other patients. The same findings are noticed
egative outcome after resective surgery is 70% lower than
Abbreviations: BPs, bisphosphonates; CI, confidence inteGraziani et al. Surgical treatment of BRONJ. J Oral Maxillofac Surg 20Numerous surgical interventions, ranging from con-
servative curettage of the necrotic lesion to major
resection/reconstruction of the necrotic portion, have
been advocated for the treatment of BRONJ.13,17,18 Usu-
lly, the decision to perform surgery reflects the attitude
f the surgeon/school because there have been no ran-
omized clinical trials evaluating the effectiveness of 1
pecific technique over another. Moreover, the differ-
nt ways in which the disease manifests may influ-
nce the decision as to whether to perform surgery.
n analysis of the present data indicated that resective
urgery can effect a clinical improvement because
lmost 70% of the patients showed disease regression.
hese results are significant because minor resective
urgery has been used in more advanced cases (stages
I and III), has limited morbidity, and may be per-
ormed with patients under only local anesthesia. The
resent data are in agreement with previous reports
dvocating resective surgery as an elective tech-
ique.19-21 Carlson et al.14 reported a success rate of
1% in 82 patients. These findings also are confirmed
n 1 of the few prospective studies on BRONJ surgery,
hich showed that the minimal resection of necrotic
one and the closure of local soft tissue could be
easible treatment strategies to achieve clinical im-
rovement 6 months after surgery.22
Conversely, conservative surgical treatment, namely
the surgical removal/debridement of necrotic tissues,
has yielded controversial results. Surprisingly, less se-
vere cases, such as stage I, treated mainly with local
debridement have not shown the same positive out-
comes as noted in more advanced cases. Approxi-
mately half of those treated with local debridement
do not show clinical improvement. Stanton and Bala-
sanian23 retrospectively analyzed 30 patients affected
INFLUENCING A POSITIVE OUTCOME
ps OR (95% CI) P Value
1.1 (0.9-1.04) .4
1.4 (0.8-2.6) .3
0.4 (0.2-0.7) .009
0.6 (0.3-1.1) .1
0.6 (0.3-1.2) .2
atment 0.4 (0.2-0.8) .009
1 (0.9-1.03) .9
1.3 (0.8-2) .3
1.1 (0.9-1.5) .2
n 0.3 (0.2-0.7) .004
nst a negative outcome, whereas an odds ratio higher than
ts were obtained for surgical intervention, corticosteroid
th corticosteroids to have a negative outcome is 60% lower
sions located in the maxilla. The probability to achieve a
local debridement.
R, odds ratio.TORS
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2506 SURGICAL TREATMENT OF BRONJby BRONJ lesions treated with surgical debridement.
Twenty-five patients showed a significant benefit, re-
sulting in clinical success. However, no information
on the stage of the disease before surgery and no
follow-up on relapses were provided. Stockmann et
al24 reported an 89% success rate 1 year after conser-
vative surgery in 50 patients. Another report on 24
subjects treated with the removal of necrotic bone
showed failure in only 4 subjects with stage III le-
sions.17 According to these investigators, conserva-
tive treatment may be a successful option for less
advanced cases.
Some additional factors can affect outcome. From
an epidemiologic point of view, lesions are more
frequently associated with the mandible.23,25-27 This is
robably due to the minor thickness of the mucosa
nd its lower vascularization compared with that of
he maxilla. Indeed, an analysis of the present data
ndicated that maxillary lesions have a better prog-
osis. BRONJ is strongly associated with an onco-
ogic diagnosis. These findings are compatible with
hose of previously reported studies.28,29 However,
he positive association between the oral adminis-
ration of BPs and a positive surgical outcome dis-
grees somewhat with previous reports based on
maller samples.17
Surgical outcome also appears to be influenced by
corticosteroid therapy. Indeed, corticosteroids ap-
pear to be associated with more severe BRONJ le-
sions, with an unpredictable prognosis.30 Steroids are
outinely incorporated into anticancer therapeutic
egimens and may be administered intravenously or
rally. Although steroid use has long been associated
ith osteonecrosis of the long bones, the role of
orticosteroids in the pathogenesis of osteonecrosis is
nclear.31,32 Therefore, a possible role of corticoster-
id cessation during treatment needs further investi-
ation.
The literature has reported various surgical options
or the treatment of advanced BRONJ. However, the
verall results can be affected by some possible bi-
ses. Most studies are retrospective. Moreover, the
ample size is rarely comprised of more than 100
ubjects, and short follow-ups are often reported.
herefore, the results may reflect the positive clinical
cenario of a specific center more than the predict-
bility of the technique. Also, 1 study did not take into
ccount the levels of terminal C-telopeptide because
ost patients received treatment before C-telopep-
ide levels were found to be useful risk predictability
arkers.9 However, many studies have not confirmed
the effectiveness of this test for patients with cancer
or osteoporosis.33-36
The retrospective nature of the present study is
counterbalanced by the larger sample of cases of
surgical treatment of BRONJ than reported in the restof the literature. However, further research based on
prospective studies is needed to clarify these findings.
Surgical treatment options for BRONJ are still under
debate, and no evidence-based guidelines are avail-
able. An analysis of the present data indicated that
local debridement and resective surgery resulted in an
improvement, albeit modest, in the overall clinical
condition. Resective surgery appeared to be associ-
ated with a higher rate of clinical success compared
with local debridement.
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